Abstract
Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk factors for the development of HCC. Currently, the treatment options are rather limited, and the prognosis for this malignancy is poor for most of these patients. RNA interference has emerged as an innovative technology for gene silencing and as a potential therapeutic for various diseases, including cancer. HCC has been widely chosen as a model system for the development of RNAi therapy due to the convenience and availability of effective delivery of RNA molecules into liver tissues. Targets for HCC treatment include HBV and HCV viruses, oncogenes, as well as cellular genes mediating angiogenesis, tumor growth and metastasis. Here, we summarized the progress of RNAi therapeutics in HCC treatment, relevant patents, potential challenges and prospects in the future.
Keywords: HCC, RNAi, Hepatocellular carcinoma, aflatoxin B1, Akt signaling, hepatocarcinogenesis, VEGFR, Drosha's cleavage, transcriptional gene silencing, RISC, TERT, IRES, DICER1, cadherin-17, STAT3, TGFBR, FoxM1B, CIAPIN1, metalloprotease, Transferrin, ALN-VSP02, SNALPs
Recent Patents on Anti-Cancer Drug Discovery
Title: RNA Interference as Therapeutics for Hepatocellular Carcinoma
Volume: 6 Issue: 1
Author(s): Chuanrui Xu, Susie A. Lee and Xin Chen
Affiliation:
Keywords: HCC, RNAi, Hepatocellular carcinoma, aflatoxin B1, Akt signaling, hepatocarcinogenesis, VEGFR, Drosha's cleavage, transcriptional gene silencing, RISC, TERT, IRES, DICER1, cadherin-17, STAT3, TGFBR, FoxM1B, CIAPIN1, metalloprotease, Transferrin, ALN-VSP02, SNALPs
Abstract: Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk factors for the development of HCC. Currently, the treatment options are rather limited, and the prognosis for this malignancy is poor for most of these patients. RNA interference has emerged as an innovative technology for gene silencing and as a potential therapeutic for various diseases, including cancer. HCC has been widely chosen as a model system for the development of RNAi therapy due to the convenience and availability of effective delivery of RNA molecules into liver tissues. Targets for HCC treatment include HBV and HCV viruses, oncogenes, as well as cellular genes mediating angiogenesis, tumor growth and metastasis. Here, we summarized the progress of RNAi therapeutics in HCC treatment, relevant patents, potential challenges and prospects in the future.
Export Options
About this article
Cite this article as:
Xu Chuanrui, A. Lee Susie and Chen Xin, RNA Interference as Therapeutics for Hepatocellular Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793980097
DOI https://dx.doi.org/10.2174/157489211793980097 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Realgar Nanoparticles Inhibit Migration, Invasion and Metastasis in a Mouse Model of Breast Cancer by Suppressing Matrix Metalloproteinases and Angiogenesis
Current Drug Delivery Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Near-infrared Light Responsive Upconversion Nanoparticles for Imaging, Drug Delivery and Therapy of Cancers
Current Nanoscience The Pathogenesis, Complications and Therapeutic Strategy for Hepatitis C Virus-associated Insulin Resistance in the Era of Anti-viral Treatment
Reviews on Recent Clinical Trials Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Chalcones in Cancer: Understanding their Role in Terms of QSAR. II Part
Mini-Reviews in Medicinal Chemistry Bid Stands at the Crossroad of Stress-Response Pathways
Current Cancer Drug Targets Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Novel Concepts for Anti-Infective Activity of Cytokines, Chemokines and Diverse Agents
Recent Patents on Anti-Infective Drug Discovery Toxicity and Surface Modification of Dendrimers: A Critical Review
Current Drug Delivery Evaluation of Direct Effect of Testosterone on NGEP and LM O1 Expression in LNCaP Prostate Cancer Cells
Current Biomarkers (Discontinued) Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy An Overview on the Importance of Combining Complementary Analytical Platforms in Metabolomic Research
Current Topics in Medicinal Chemistry Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Marine Microbes-Derived Anti-Bacterial Agents
Mini-Reviews in Medicinal Chemistry Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem
Cardiovascular & Hematological Disorders-Drug Targets